Document ID: chunk:federal_register_of_legislation:F2021L00601:reg:9:p3
Version: federal_register_of_legislation:F2021L00601
Segment Type: reg
Provision Reference: reg 9 (pt 3/3)
Character Range: 9877–10875

the time of the clinical worsening of gastro-oesophageal reflux disease;
Note: specified list of disorders of mental health is defined in the Schedule 1 - Dictionary.
(22)      taking orally a drug from the Specified List 2 of drugs at the time of the clinical worsening of gastro-oesophageal reflux disease;
Note: Specified List 2 of drugs is defined in the Schedule 1 - Dictionary.
(23)      taking orally a drug which is associated in the individual with the clinical worsening of gastro-oesophageal reflux disease during drug therapy and either:
(a)           the improvement of gastro-oesophageal reflux disease within 3 months of discontinuing or tapering drug therapy; or
(b)          the clinical worsening of gastro-oesophageal reflux disease on rechallenge with the same drug; and
where the drug was being taken at the time of the clinical worsening of gastro-oesophageal reflux disease;
(24)      inability to obtain appropriate clinical management for gastro-oesophageal reflux disease.